These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36960592)

  • 1. Respiratory syncytial virus infection and the need for immunization in Korea.
    Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
    Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccines against respiratory syncytial virus.
    Yang K; Varga SM
    Curr Opin Virol; 2014 Jun; 6():78-84. PubMed ID: 24794644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
    Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
    N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus vaccine: where are we now and what comes next?
    Noor A; Krilov LR
    Expert Opin Biol Ther; 2018 Dec; 18(12):1247-1256. PubMed ID: 30426788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
    Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
    Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host Responses to Respiratory Syncytial Virus Infection.
    Agac A; Kolbe SM; Ludlow M; Osterhaus ADME; Meineke R; Rimmelzwaan GF
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults.
    Tenenbaum T; Liese J; Welte T; Rademacher J
    Dtsch Arztebl Int; 2024 May; 121(9):303-312. PubMed ID: 38652840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.